BOCA RATON, FLORIDA - Akron Biotech, an innovative biotech company focused on serving the growing demands of the cell therapy industry, is pleased to announce it was awarded a Phase 1 Small Business Innovative Research (SBIR) Award from the National Institutes of Health (NIH) to develop enzyme-based formulations for the isolation of stem cells from various tissues. The project is in collaboration with Dr. Gregg Fields, Vice President of Scientific Affairs at Torrey Pines Institute for Molecular Studies, and will involve the use of novel engineered enzyme formulations to improve viability and quality of isolated stem cells with no toxicities.
The Phase I project proposes an alternative to develop and use optimal formulations of a family of novel engineered enzymes capable of catalyzing the degradation of virtually all extracellular matrix (ECM) components, with the goal of liberating viable stem cells with good and stable proliferative capabilities. The overall impact is also significant for the future treatment of a broad array of tissues.
The project, conducted in collaboration with the Torrey Pines Institute for Molecular Studies, in Port St. Lucie, Florida, will involve studies directed toward the commercialization of the product. Akron Biotech will manufacture and commercialize kits for tissue dissociation and develop further therapeutic applications for a wide variety of diseases.
“We are pleased to have been awarded this grant as it will allow us to significantly advance the isolation of stem cells that are crucially necessary for the treatment of a variety of acute diseases. This is a critical step toward improving healthcare and advancing cell therapies,” said Claudia Zylberberg, PhD., Founder and CEO of Akron Biotech.
“We are excited about this Phase I SBIR award from the NIH, as it validates the significance of the technology we are developing,” stated Gregg Fields. “This work with Akron Biotech is perfectly aligned with Torrey Pines Institute’s mission to improve human health through innovation and advanced technologies.”
About Akron Biotech
Akron Biotech is an innovative biotechnology company headquartered in South Florida, U.S., with a strategic focus on supplying GMP-qualified raw materials and services to the regenerative medicine industry. As a global supplier, Akron manufactures a range of products for cell therapy discovery, development and commercialization. As an ISO 9001-certified company, Akron supports clients with rigorous documentation and quality standards to fulfill their regulatory demands. Our team works at length on innovation in process and development of products to better serve the industry and drive the emerging regenerative medicine sector to unmet clinical needs through affordable and seamless manufacturing options.
1095 Broken Sound Pkwy
Boca Raton FL 33446
Phone: (561) 750-6120
The mission of the Small Business Innovation Research program is to support scientific excellence and technological innovation through the investment of Federal research funds in critical American priorities to build a strong national economy. Through a competitive awards-based program, SBIR enables small businesses to explore their technological potential, and provides the incentive to profit from its commercialization. For more information, visit www.sbir.gov.